ALPS12 + obinutuzumab
Phase 1Recruiting 2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive Stage Small Cell Lung Cancer
Conditions
Extensive Stage Small Cell Lung Cancer
Trial Timeline
Oct 8, 2025 → Sep 30, 2028
NCT ID
NCT07107490About ALPS12 + obinutuzumab
ALPS12 + obinutuzumab is a phase 1 stage product being developed by Chugai Pharmaceutical for Extensive Stage Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07107490. Target conditions include Extensive Stage Small Cell Lung Cancer.
What happened to similar drugs?
0 of 11 similar drugs in Extensive Stage Small Cell Lung Cancer were approved
Approved (0) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07107490 | Phase 1 | Recruiting |
Competing Products
20 competing products in Extensive Stage Small Cell Lung Cancer